The FDA has approved Anoro Ellipta (umeclidinium and vilanterol; GSK and Theravance) inhalation powder for the once-daily, long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD).
Anoro Ellipta combines umeclidinium 62.5mcg, a long-acting muscarinic antagonist, and vilanterol 25mcg, a long-acting beta2 agonist.
Umeclidinium affects the muscles around the large airways and stops the muscles from tightening, and vilanterol improves breathing by relaxing the muscles of the airways to allow more air to flow into and out of the lungs.
The safety and efficacy of Anoro Ellipta were evaluated in over 2,400 patients with COPD. Treatment with Anoro Ellipta showed improved lung function compared to placebo.
Anoro Ellipta will be supplied as a disposable inhaler containing 2 double-foil blister strips with 30 blisters each. It is expected to be available during the first quarter of 2014.